Troy Wilson, Kura Oncology CEO
February 24, 2023 11:01 AM ESTUpdated 02:58 PM
R&D

Ku­ra On­col­o­gy drops mul­ti­ple clin­i­cal pro­grams for J&J-dis­cov­ered tip­i­farnib

Paul Schloesser

Associate Editor

Ku­ra On­col­o­gy is ax­ing all but one clin­i­cal de­vel­op­ment pro­gram in­volv­ing an old Janssen can­di­date.

Ac­cord­ing to an SEC fil­ing on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times